Novavax: Balancing Potential and Risk Amid Strategic Shifts and Uncertain Market Outlook
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
Business Insider12h
Novavax’s Market Share and Pipeline Uncertainties Lead to Sell Rating
J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price target of $9.00. Eric Joseph has given his Sell rating due to a combination of ...
GlobalData on MSN23h
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...
pharmaphorum17h
Novavax: Creating tomorrow’s vaccines today
Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...
MarketWatch21h
Novavax Inc.
Inovio Pharmaceuticals Inc. 0.36% $143.32M ...